 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...119120121122123124125126127128129...235236» |
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
IRREVERSIBLE PANCREATIC ELECTROPORATION, FIRST INSTITUTIONAL EXPERIENCE, CASE REPORT AND LITERATURE REVIEW () - Oct 6, 2021 - Abstract #AHPBA2021AHPBA_663;
And this is reflected in stable ECOGs for a longer time. (2,3) Although in Mexico there is the possibility of using this type of tech- nology, they are limited by their high cost, even so, The Instituto Jalisciense de Cancerología is a pioneer in the comprehensive management of locally advanced pancreatic cancer, positioning itself as a reference center in the country.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
EFFECT OF DIABETES AND SMOKING ON THE PATHOLOGICAL RESPONSE OF NEOADJUVANT THERAPY IN PANCREATIC ADENOCARCINOMA () - Oct 6, 2021 - Abstract #AHPBA2021AHPBA_632;
Our results demonstrate that a diagnosis of Diabetes was associated with a significantly increased chance of predicting poor pathologic response to neoadju- vant therapy. This warrants the need for further discussion and randomized controlled trials to study patient factors which influence pathologic response to neoadjuvant ther- apy, which can help improve patient selection for neoad- juvant treatment.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
COMBINED EN-BLOC RESECTION OF CELIAC AND SUPERIOR MESENTERIC ARTERIES IN SURGICAL MANAGEMENT OF LOCALLY ADVANCED PANCREATIC CANCER () - Oct 6, 2021 - Abstract #AHPBA2021AHPBA_608;
Our patient’s length of stay were short without pancreatic spe- cific or vascular bypass specific complication. This option can be offered to selected group of patients with good performance status who demonstrated stability of the dis- ease on chemotherapy.
- | Vectibix (panitumumab) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: TRIPLETE: First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS (clinicaltrials.gov) - Oct 6, 2021
P3, N=432, Active, not recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
This option can be offered to selected group of patients with good performance status who demonstrated stability of the dis- ease on chemotherapy. Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Sep 2022 | Trial primary completion date: Dec 2020 --> Apr 2022
- || cisplatin / Generic mfg.
Review, Journal: Management of sinonasal adenocarcinomas with anterior skull base extension. (Pubmed Central) - Oct 6, 2021
Neoadjuvant chemotherapy can be indicated in selected cases. The role of biotherapy and immune therapy still needs to be elucidated.
- || oxaliplatin / Generic mfg.
Clinical, Journal: The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Non-alcoholic Fatty Liver Disease. (Pubmed Central) - Oct 6, 2021
Oxaliplatin is an alkylating agent given with fluorouracil and leucovorin as a mainstay adjuvant chemotherapy for stage III colorectal cancer (CRC). No abstract available
- ||| pegilodecakin (LY3500518) / Eli Lilly
Clinical, P3 data, Journal: Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). (Pubmed Central) - Oct 6, 2021
Safety findings were consistent as previously observed from PEG with chemotherapy; toxicity was manageable and tolerable. Exploratory pharmacodynamic results were consistent with immunostimulatory signals of the IL-10R pathway.
- ||| Braftovi (encorafenib) / Pfizer
Enrollment open, Metastases: NAUTICALCRC: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. (clinicaltrials.gov) - Oct 5, 2021
P2, N=103, Recruiting, Sponsor: Pierre Fabre Medicament
Exploratory pharmacodynamic results were consistent with immunostimulatory signals of the IL-10R pathway. Not yet recruiting --> Recruiting
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Akkermansia Muciniphila Potentiates the Antitumor Efficacy of FOLFOX in Colon Cancer. (Pubmed Central) - Oct 5, 2021
Last, metabolomics analysis suggested dipeptides containing branched-chain amino acid (BCAA) might be responsible for gut bacteria mediated FOLFOX efficacy. In conclusion, our study revealed the key role of A. muciniphila in mediating FOLFOX efficacy, and manipulating A. muciniphila might serve as a novel strategy for colon cancer therapy.
- ||| Vectibix (panitumumab) / Amgen
Biomarker, Enrollment open: An Additional Analysis of Data from the PARADIGM Exploratory Study (NCT02394834) in Patients with Advanced/Recurrent Colorectal Cancer (clinicaltrials.gov) - Oct 5, 2021
P=N/A, N=757, Recruiting, Sponsor: Takeda
In conclusion, our study revealed the key role of A. muciniphila in mediating FOLFOX efficacy, and manipulating A. muciniphila might serve as a novel strategy for colon cancer therapy. Not yet recruiting --> Recruiting
- || Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P1 trial, Combination therapy, Metastases: CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 5, 2021
P1, N=12, Not yet recruiting, Sponsor: Rafael Pharmaceuticals Inc.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
[VIRTUAL] Variability across Victorian hospitals in the care of patients with metastatic colorectal cancer: using comprehensive registry data to explore potential quality indicators. (Stream 5) - Oct 5, 2021 - Abstract #COSA2021COSA_437;
ConclusionThere is significant variation in OS for patients with mCRC in these Australian hospitals, with major differences in treatment approaches. Rates of interventions known to improve survival outcomes, such as triplet chemotherapy and resection of oligometastatic disease, may be potential QI to benchmark and track quality improvement.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
[VIRTUAL] Overall survival (OS with encorafenib (enco + cetuximab (cetux in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC. () - Oct 5, 2021 - Abstract #COSA2021COSA_184;
P3
In the BEACON CRC study (NCT02928224, median OS (95% CI with the doublet was 9.3 months (8.0–11.3 vs 5.9 months (5.1–7.1 with cetux + irinotecan or FOLFIRI (control in patients (pts with BRAF V600E-mutant mCRC (HR 0.61 [95% CI: 0.5–0.8]...Methods : OS of pts treated with the doublet or control were compared according to prior treatment with bevacizumab, oxaliplatin, or FOLFOXIRI and duration of prior anticancer therapy (ACT...This exploratory post-hoc analysis provides data that reflect the prior treatment landscape clinicians may face when deciding subsequent treatment regimens for pts with BRAF V600E-mutant mCRC. Clinical trial information: NCT02928224.
- Eyevinal (ibudilast) / MediciNova
[VIRTUAL] Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study () - Oct 5, 2021 - Abstract #COSA2021COSA_57;
Our pharmacokinetic sub-study found no change in platinum or fluorouracil levels with ibudilast.2 Aim: We aim to determine whether ibudilast can decrease acute neurotoxicity severity and CIPN in patients with metastatic CRC receiving oxaliplatin with either FOLFOX or CAPOX (+/- targeted therapy, and to determine whether ibudilast will decrease dose reductions of oxaliplatin due to neurotoxicity...Status: Study opened December 2020, five sites are recruiting, additional sites under review, four participants have been randomised to date. The study is funded by an AGITG Innovation Grant.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
[VIRTUAL] One Stage Laparoscopic Icg Guided Liver Resection For Bilateral Colorectal Liver Metastases () - Oct 5, 2021 - Abstract #ACSCLINCON2021ACS_CLINCON_3121;
ICG guided laparoscopic liver resection for bilobar liver metastases is a safe, easy reproducible and effective procedure adjuvant to LUS. Fluorescence could aid surgeons either to better staging for superficial multiple metastases or to a real-time guidance for proper transection line.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
[VIRTUAL] Alterations In Driver Genes Are Associated With Response To Neoadjuvant Folfirinox In Patients With Non-metastatic Pancreatic Ductal Adenocarcinoma (Channel 2) - Oct 5, 2021 - Abstract #ACSCLINCON2021ACS_CLINCON_2585;
SMAD4 alterations are associated with more frequent development of metastasis during neoadjuvant FOLFIRINOX and lower probability of reaching surgical resection. Further studies are needed to better define biomarkers of pathologic treatment response.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
[VIRTUAL] Susceptibility To Immune Elimination Of Epithelial And Quasi-mesenchymal Pancreatic Ductal Adenocarcinoma Cells Under Basal Conditions And Following Treatment With FOLFIRINOX (Channel 3) - Oct 5, 2021 - Abstract #ACSCLINCON2021ACS_CLINCON_1883;
Further studies are needed to better define biomarkers of pathologic treatment response. FOLFIRINOX induced increased susceptibility of PDAC cells to immune elimination irrespective of subtype and target TA expression.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] Time From Diagnosis To Chemotherapy Initiation Is Not Associated With Survival Among Patients Receiving Neoadjuvant Therapy For Pancreatic Adenocarcinoma () - Oct 5, 2021 - Abstract #ACSCLINCON2021ACS_CLINCON_426;
Delay in initiation of NAC for PDAC is not associated with survival. Patient optimization should be considered with the goal of improving tolerance of multiagent chemotherapy.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
[VIRTUAL] Semaphorin 4D Blockade Enhances T-cell Penetration And Potentiates Response To Immune Checkpoint Blockade In A Murine Model Of Pancreatic Cancer (Channel 4) - Oct 5, 2021 - Abstract #ACSCLINCON2021ACS_CLINCON_35;
Semaphorin 4D blockade is a novel immunotherapeutic strategy for sensitizing PDAC to ICB. Future clinical trials should explore the efficacy of Sema4D blockade in patients with PDAC.
- ||| MK-1084 / Merck (MSD)
New P1 trial, Monotherapy: A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov) - Oct 5, 2021
P1, N=185, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date, Trial primary completion date, Surgery, Metastases: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer (clinicaltrials.gov) - Oct 4, 2021
P1, N=21, Recruiting, Sponsor: National Cancer Institute (NCI)
Future clinical trials should explore the efficacy of Sema4D blockade in patients with PDAC. Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- || palupiprant (AN0025) / Eisai, Adlai Nortye
Trial completion, Combination therapy: PRAER 1: Preoperative Radiotherapy and E7046 in Rectum Cancer (clinicaltrials.gov) - Oct 4, 2021
P1b, N=29, Completed, Sponsor: Adlai Nortye Biopharma Co., Ltd.
Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022 Active, not recruiting --> Completed
- | New P2 trial, Metastases: GABRINOX2: Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients (clinicaltrials.gov) - Oct 3, 2021
P2, N=210, Not yet recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
- | New P2 trial: A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 3, 2021
P2, N=27, Recruiting, Sponsor: Yonsei University
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
If cDNA + after surgery , need a trial of additional 3 mo of FOLFIRI vs observation. Prob won’t matter in long term though.. Question is should we put them through TME if cDNA is still + after TNT (Twitter) - Oct 2, 2021
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Dr. @KristenCiombor with Dr. Christina Wu (who needs to get on @Twitter!), @benweinbergmd and @marshalj23 giving amazing data updates on personalized mgmt of metastatic #colorectal #cancer. 🚨 ICYMI - we're WAY past FOLFOX/FOLFIRI-Bev (Twitter) - Oct 2, 2021
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Stivarga (regorafenib) / Bayer
#CRCSM Seeking insight about tx for BRAF-mt mCRC pt with recently resected brain met (2nd episode). No other visible disease. Doc proposing Stivarga b/c passes blood-brain barrier (?). Has had CAPOX but no FOLFIRI or BEACON. @GIcancerDoc @CathyEngMD @pashtoonkasi @aparna1024 (Twitter) - Oct 2, 2021
- tremelimumab (CP-675206) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Translational program of the phase II MEDITREME trial: Identification of prognostic factors for response to durvalumab and tremelimumab in combination with FOLFOX in metastatic colorectal cancer. (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_923;
P1/2
ScRNA sequencing underlines the ability of the treatment to induce a specific immune response against neoantigens in a complete responder patient. ClinicalTrials gov Identifier: NCT03202758 Eudra-CT registration number 2016-005006-19
- mitazalimab (ADC-1013) / Alligator Biosci
OPTIMIZE-1, an open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_462;
P1, P1b/2
The study expansion includes a Simon’s two-stage design with an interim analysis to allow stopping for futility or efficacy based on ORR. Trial Registration NCT04888312
- sotigalimab (APX005M) / Apexigen
INNATE: Immunotherapy during neoadjuvant therapy for rectal cancer to elucidate local and systemic therapeutic responses. (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_406;
P2
The anti-CD40 agonist immunotherapy is emerging and APX005M has shown promise in phase I and ongoing phase II trials...It serves as an important platform for scientific and clinical investigation. Clinicaltrials gov: NCT04130854
- CYAD-101 / Celyad Oncology, Keytruda (pembrolizumab) / Merck (MSD)
A Phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_404;
P1
Methods The KEYNOTE-B79 trial evaluates the safety and clinical activity of multiple infusions of CYAD-101, administered post FOLFOX preconditioning chemotherapy, then followed three weeks after CYAD-101 by a pembrolizumab consolidation treatment (200 mg every three weeks for a maximum two years total treatment duration) in microsatellite stable/mismatch-repair proficient mCRC patients with recurrent/progressing disease after at least one metastatic line of therapy which must include FOLFOX chemotherapy.The schedule of administration of three CYAD-101 infusions at the dose 1x109 cells/infusion Q2W post-FOLFOX preconditioning chemotherapy are based on the alloSHRINK study.This sequencing of checkpoint inhibitor at a timepoint after CYAD-101 therapy ensures that the modulated endogenous immune response is enabled by pembrolizumab. This study is not focused on impacting the CAR T cell itself largely since CYAD-101 cells at the time of manufacture show negligible expression of PD-1 and that this sequencing ensures no overlap of potential toxicities that could arise from the CAR T or checkpoint inhibitor therapies.The KEYNOTE-B79 study is planned to be initiated in Q4-2021.
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Changes and Prognostic Value of lncRNA CASC9 in Patients with Advanced Colon Cancer after Chemotherapy. (Pubmed Central) - Oct 1, 2021
With increased expression of serum lncRNA CASC9, patients with ACC suffered an unfavorable chemotherapy effect. In addition, serum lncRNA CASC9 is a promising sensitive indicator for prediction of ACC and is related to the clinical efficacy and prognosis of patients.
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: How many pts were treated with 2nd line regimens once they progressed? Remember for tumors that have effective 2nd line regimens trying to correlate PFS & OS can be tricky. The advantage of FOLFOX could be negated if surgery only group were allowed to be treated once they failed (Twitter) - Oct 1, 2021
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
I will plan with cardiology and admit to ccu and resume FOLFIRINOX, I will still give it a go , this is the next regimen and I will still try to administer it. Had similar case and had to admit to ccu for every cycle with no major issue as Pt was well covered by prophylactic meds (Twitter) - Oct 1, 2021
- | Trial completion date, Trial primary completion date, Combination therapy: Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI (clinicaltrials.gov) - Oct 1, 2021
P1, N=16, Recruiting, Sponsor: University of Massachusetts, Worcester
In addition, serum lncRNA CASC9 is a promising sensitive indicator for prediction of ACC and is related to the clinical efficacy and prognosis of patients. Trial completion date: Sep 2021 --> Sep 2023 | Trial primary completion date: Aug 2021 --> Aug 2023
- || Lynparza (olaparib) / Merck (MSD), AstraZeneca, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Review, Journal, BRCA Biomarker, PARP Biomarker: Pancreatic Cancer: A Review. (Pubmed Central) - Oct 1, 2021
For the 5% to 7% of patients with a BRCA pathogenic germline variant and metastatic PDAC, olaparib, a poly (adenosine diphosphate [ADB]-ribose) polymerase inhibitor, is a maintenance option that improves progression-free survival following initial platinum-based therapy...Currently available cytotoxic therapies for advanced disease are modestly effective. For all patients, multidisciplinary management, comprehensive germline testing, and integrated supportive care are recommended.
- |||| Sulanda (surufatinib) / Hutchmed
Enrollment open, Metastases: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma (clinicaltrials.gov) - Sep 30, 2021
P3, N=194, Recruiting, Sponsor: Hutchison Medipharma Limited
For all patients, multidisciplinary management, comprehensive germline testing, and integrated supportive care are recommended. Not yet recruiting --> Recruiting
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Had a similar case with FOLFOX. Patient had ST changes on EKG 24-48 hours post Rx. Vasospasms. Cath was negative. Re-challenged with calcium channel blocker and Cardiology on board. Skipped 5FU bolus while the patient was in inpatients settings. Would consider re-challenging. (Twitter) - Sep 30, 2021
- |||||||||| Vectibix (panitumumab) / Amgen
New P3 trial: FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer. folfoxiri pi (EUDRACT) - Sep 30, 2021
P3, N=432, Ongoing, Sponsor: Fondazione GONO
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: #MedOncTwitter #PancreaticCancer colleagues, I just had a real dilemma and I need some opinions/guidance (1/3): Young patient with extensive metastatic pancreatic cancer. Started FOLFIRINOX on 09/27/21, and had very clearly documented coronary vasospasm the next day!! (Twitter) - Sep 30, 2021
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Great & thoughtful editorial! Channelling my inner @HalletJulie: PFS is an underrated metric- might signify⬇️time on chemo& more time at home. Neuropathy from FOLFOX may still triumph in this trial, but only way to find out is integrating👆pt-centric measures into cancer trials. (Twitter) - Sep 30, 2021
- | Avastin (bevacizumab) / Roche
New P2 trial, Circulating tumor DNA: CtDNA-Directed Post-Hepatectomy Chemotherapy for Patients with Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Sep 30, 2021
P2, N=120, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| Lonsurf (trifluridine/tipiracil) / Otsuka
New P2 trial: ERASE-CRC: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (clinicaltrials.gov) - Sep 30, 2021
P2, N=300, Not yet recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal, Liquid biopsy, BRCA Biomarker: BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer. (Pubmed Central) - Sep 30, 2021
Not yet recruiting --> Recruiting No abstract available
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Review, Journal: Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review. (Pubmed Central) - Sep 30, 2021
Median progression-free and overall survival for resected patients were 12.9 and 30 months, respectively, versus 13.2 months overall survival for unresected patients. In conclusion, although there is wide variability in reported LAPDAC resection rates post-neoadjuvant chemotherapy, retrospective data suggest that neoadjuvant treatment followed by surgery results in improved survival.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical, Observational data, Journal: FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the Japan Adjuvant Study Group of Pancreatic Cancer 06. (Pubmed Central) - Sep 30, 2021
In conclusion, although there is wide variability in reported LAPDAC resection rates post-neoadjuvant chemotherapy, retrospective data suggest that neoadjuvant treatment followed by surgery results in improved survival. The toxicity and tolerability of FOLFIRINOX for recurrence after pancreatic resection were similar to those for locally advanced or metastatic disease with appropriate patient selection and dose modifications.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. (Pubmed Central) - Sep 30, 2021
Microscopic margin positivity is not associated with recurrence and survival in localized PDAC patients resected after treatment with NAC. Aggressive surgical extirpation in high volume centers should be considered in selected patients after extensive NAC.
- || 5-fluorouracil / Generic mfg., Levofolinate / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Observational data, Journal, Combination therapy: Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen. (Pubmed Central) - Sep 30, 2021
Aggressive surgical extirpation in high volume centers should be considered in selected patients after extensive NAC. Na-Lev showed a reassuring toxicity profile and a favorable impact on drug preparation and administration.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., carboplatin / Generic mfg.
Retrospective data, Review, Journal: Relative Dose Intensity of Chemotherapy and Survival in Advanced Stage Solid Tumor Cancer Patients: A Systematic Review and Meta-Analysis. (Pubmed Central) - Sep 30, 2021
Results of this systematic review and meta-analysis, evaluating the impact of relative dose intensity (RDI) on survival in solid tumor cancer patients on nonadjuvant-based chemotherapy regimens, demonstrate a longer overall survival with RDI levels of at least 80% for solid tumor cancer patients on carboplatin-based and FOLFOX-/FOLFIRI/FOLFIRINOX-based chemotherapy regimens, suggesting a protective effect of maintaining RDI ≥80 or ≥85%. While grade 3 or higher hematologic toxicities occurred more in carboplatin-based studies, managing toxicities across treatment regimens may contribute to maintenance of higher RDI and ultimately benefit overall survival.